OncoMatch/Clinical Trials/NCT07358806
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Is NCT07358806 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including OCT-598 and Docetaxel for solid tumor.
Treatment: OCT-598 · Docetaxel — This is a Phase 1 study intended to determine the MTD of OCT-598 following multiple-dose therapy and to establish the RP2D for OCT-598 as a single agent, by assessing its safety and tolerability as monotherapy and in combination with standard-of-care treatments in patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Breast Carcinoma
Head and Neck Squamous Cell Carcinoma
Non-Small Cell Lung Carcinoma
Prostate Cancer
Gastric Cancer
Esophageal Carcinoma
Prior therapy
Cannot have received: EP2 antagonist
Prior treatment with an EP2 and/or EP4 antagonist.
Cannot have received: docetaxel (docetaxel)
Exception: patients who have not received prior docetaxel in the advanced setting are eligible (Part B)
Docetaxel-appropriate (Part B): patients who have not received prior docetaxel in the advanced setting are eligible
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5 × 10^9/L; Platelets ≥100,000/μL; Hemoglobin ≥9.0 g/dL
Kidney function
Creatinine clearance calculated using the Cockcroft-Gault formula ≥60 mL/min
Liver function
Total bilirubin <1.5 × ULN; ALT or AST ≤2.5 × ULN
Cardiac function
LVEF >50% or within institutional values; Mean resting corrected QT (QTc) interval using Fridericia's formula (QTcF) >470 ms, regardless of gender, or history of additional risk factors for torsades de pointes (eg, heart failure, hypokalemia, family history of long QT syndrome). Patients with left bundle block or atrial fibrillation are eligible if QTc cannot be accurately calculated provided that there is no prior history of prolonged QTc.
Adequate organ and marrow function, defined as follows: Absolute neutrophil count ≥1.5 × 10^9/L; Platelets ≥100,000/μL; Hemoglobin ≥9.0 g/dL; Total bilirubin <1.5 × ULN; ALT or AST ≤2.5 × ULN; Creatinine clearance calculated using the Cockcroft-Gault formula ≥60 mL/min; LVEF >50% or within institutional values; Mean resting corrected QT (QTc) interval using Fridericia's formula (QTcF) >470 ms, regardless of gender, or history of additional risk factors for torsades de pointes (eg, heart failure, hypokalemia, family history of long QT syndrome).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify